News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MediciNova, Inc. To Present Data On MN-001 For The Treatment Of NASH (Nonalcoholic Steatohepatitis) During The JDDW 2014 (Japan Digestive Disease Week 2014)


7/8/2014 6:16:41 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LA JOLLA, Calif., July 7, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will present at the 56th Annual Meeting of the Japanese Society of Gastroenterology and the 18th General Meeting of the Japan Society of Hepatology during the Japan Digestive Disease Week (JDDW) 2014 in Kobe, Japan.

Preclinical data have demonstrated the benefits of MN-001 for the treatment of NASH (nonalcoholic steatohepatitis) in an animal model. The presentation at the 56th Annual Meeting of the Japanese Gastroenterology and the 18th General Meeting of the Japan Society of Hepatology will extend understanding about the mechanism by which MN-001 improves pathology in NASH, for which there is a large unmet medical need.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES